Printer Friendly

CYTOMED PROMOTES MICHAEL E. FITZGERALD TO VICE PRESIDENT, CHIEF FINANCIAL OFFICER

 CAMBRIDGE, Mass., April 27 /PRNewswire/ -- CytoMed, Inc. today announced that Michael E. Fitzgerald has been promoted to vice president, chief financial officer. Fitzgerald joined CytoMed in 1992 as director of finance and administration. He has 18 years of experience in corporate accounting, including 10 years with the Amicon Division of W.R. Grace & Co., and five years with BioTechnica International, Inc.
 "Michael's extensive experience in building financial operations has added tremendous value to CytoMed during the past year," commented Thomas R. Beck, M.D., CytoMed's chairman and chief executive officer. "His more than 18 years of financial systems design expertise and industry experience are increasingly important to CytoMed as we continue to move toward advancement of our lead dual function antagonist program. We look forward to Michael's continued success as CytoMed's chief financial officer."
 Prior to joining CytoMed, Fitzgerald, 39, served as corporate controller and chief accounting officer for TSI Corporation of Worcester. From 1986 to 1991 Fitzgerald served as corporate controller, assistant treasurer and chief accounting officer at BioTechnica International, Inc. of Cambridge. He also served for 10 years at the Amicon Division, W.R. Grace and Co., as a divisional accountant, and most recently as manager of corporate accounting. He holds a B.S. degree in Economics and Finance, and an M.B.A., Finance Concentration, from Bentley College in Waltham, Mass.
 CytoMed is engaged in the discovery, development and commercialization of novel, proprietary treatments for disorders involving inflammation and the immune response. CytoMed's technology offers the potential for revolutionizing the treatment of inflammatory and immune systems disorders based on the development of pharmaceuticals having new mechanisms of action. The company's headquarters are in Cambridge, Mass.
 -0- 4/27/93
 /CONTACT: Thomas R. Beck, M.D. of CytoMed, Inc., 617-661-3400; or Lynne H. Brum of Feinstein Partners, 617-577-8110, for CytoMed/


CO: CytoMed, Inc. ST: Massachusetts IN: MTC SU: PER

CH -- NE002 -- 1210 04/27/93 09:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:320
Previous Article:GREEN TREE FINANCIAL CORPORATION DECLARES CASH DIVIDEND
Next Article:ZIFFNET LAUNCHES ZIFFNET SELECTIONS FOR APPLELINK; ZIFFNET/MAC NEWS, PRODUCT REVIEWS AND SOFTWARE NOW AVAILABLE ON APPLELINK
Topics:


Related Articles
STEVE E. REESE JOINS CYTOMED AS VICE PRESIDENT, BUSINESS DEVELOPMENT
CYTOMED, INC. EXPANDS SCIENTIFIC TEAM -- ADDS SENIOR DIRECTOR, MEDICINAL CHEMISTRY AND PRINCIPAL SCIENTIST
CytoMed Appoints Richard Woodrich Executive Vice President and COO
American Biogenetic Sciences Inc. Appoints Stephen H. Ip, Ph.D, Executive Vice President and Chief Operating Officer
James P. Feeney Joins Vertex Pharmaceuticals as Senior Director of Business Development
Therion Appoints Richard Woodrich as Senior Vice President, Business Development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters